|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZIM3 |
Gene summary for ZIM3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZIM3 | Gene ID | 114026 |
| Gene name | zinc finger imprinted 3 | |
| Gene Alias | ZNF264 | |
| Cytomap | 19q13.43 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96PE6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114026 | ZIM3 | HCC1 | Human | Liver | HCC | 1.08e-05 | 5.88e-01 | 0.5336 |
| 114026 | ZIM3 | HCC2 | Human | Liver | HCC | 4.05e-12 | 9.81e-01 | 0.5341 |
| 114026 | ZIM3 | HCC5 | Human | Liver | HCC | 3.09e-02 | 6.24e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZIM3 | SNV | Missense_Mutation | novel | c.1067T>G | p.Ile356Ser | p.I356S | Q96PE6 | protein_coding | tolerated(0.21) | probably_damaging(0.973) | TCGA-CR-6474-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unspecific | PD | |
| ZIM3 | SNV | Missense_Mutation | novel | c.593A>G | p.His198Arg | p.H198R | Q96PE6 | protein_coding | tolerated(0.68) | benign(0) | TCGA-CR-7398-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | rs557421274 | c.541N>T | p.Arg181Cys | p.R181C | Q96PE6 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | rs539722568 | c.1403G>T | p.Arg468Ile | p.R468I | Q96PE6 | protein_coding | deleterious(0) | benign(0.009) | TCGA-F7-7848-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | novel | c.62N>G | p.Glu21Gly | p.E21G | Q96PE6 | protein_coding | deleterious(0) | benign(0.285) | TCGA-HC-A8D1-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | novel | c.1025N>T | p.Lys342Met | p.K342M | Q96PE6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-XK-AAJP-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | rs774474471 | c.364G>A | p.Gly122Arg | p.G122R | Q96PE6 | protein_coding | tolerated(0.53) | benign(0.006) | TCGA-BR-8284-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ZIM3 | SNV | Missense_Mutation | novel | c.309N>C | p.Glu103Asp | p.E103D | Q96PE6 | protein_coding | tolerated(0.3) | benign(0.026) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| ZIM3 | SNV | Missense_Mutation | c.213A>C | p.Glu71Asp | p.E71D | Q96PE6 | protein_coding | tolerated(0.6) | benign(0.05) | TCGA-HU-A4GH-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZIM3 | SNV | Missense_Mutation | novel | c.743N>G | p.Glu248Gly | p.E248G | Q96PE6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-RD-A8N6-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |